ProAxsis And Aptamer Group, The Developer Of Custom Affinity Ligands To Enable The Life Science Industry Through Its Proprietary OptimerTM Platform Announce A Partnership To Develop Optimer Ligands For ProAxsis’s Diagnostic Assays. Aptamer Group Will Develop Validated Optimer Ligands Against Critical Targets For ProAxsis’s Diagnostic Assays.(August 2021) - ProAxsis

ProAxsis and Aptamer Group, the developer of custom affinity ligands to enable the life science industry through its proprietary OptimerTM platform announce a partnership to develop Optimer ligands for ProAxsis’s diagnostic assays. Aptamer Group will develop validated Optimer ligands against critical targets for ProAxsis’s diagnostic assays.(August 2021)

WP_Developer

November 11, 2022

Recent Posts

ProAxsis attends The Bio International Convention June 5-8, 2023

American Thoracic Society Annual Meeting Washington DC, 19-24 May 2023

November 11, 2022

Association of Medical Diagnostics Manufacturers IVD Regulatory Meeting Bethesda, MD 19-20 April,2023

November 11, 2022

Have Any Questions?

Categories

PR8

November 11, 2022

Share This :